News Column

New Findings from Sloan Kettering Institute Yields New Data on Nucleic Acid Therapeutics

June 18, 2014

By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Biotechnology. According to news reporting from New York City, New York, by NewsRx journalists, research stated, "Monoclonal antibodies (mAbs) have naturally evolved as suitable, high affinity and specificity targeting molecules. However, the large size of full-length mAbs yields poor pharmacokinetic properties."

The news correspondents obtained a quote from the research from Sloan Kettering Institute, "A solution to this issue is the use of a multistep administration approach, in which the slower clearing mAb is administered first and allowed to reach the target site selectively, followed by administration of a rapidly clearing small molecule carrier of the cytotoxic or imaging ligand, which bears a cognate receptor for the mAb. Here, we introduce a novel pretargetable RNA based system comprised of locked nucleic acids (LNA) and 2'O-Methyloligoribonucleotides (2'OMe-RNA). The duplex shows fast hybridization, high melting temperatures, excellent affinity, and high nuclease stability in plasma."

According to the news reporters, the research concluded: "Using a prototype model system with rituximab conjugated to 2'OMe-RNA (oligo), we demonstrate that LNA-based complementary strand (c-oligo) effectively hybridizes with rituximab-oligo, which is slowly circulating in vivo, despite the high clearance rates of c-oligo."

For more information on this research see: A self-assembling short oligonucleotide duplex suitable for pretargeting. Nucleic Acid Therapeutics, 2013;23(4):289-99. (Mary Ann Liebert, Inc. -; Nucleic Acid Therapeutics -

Our news journalists report that additional information may be obtained by contacting P. Mallikaratchy, Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, New York, New York 10065, United States. Additional authors for this research include J. Gardner, L.U. Nordstrom, N.J. Veomett, M.R. McDevitt, M.L. Heaney and D.A Scheinberg (see also Biotechnology).

Keywords for this news article include: Antineoplastic Monoclonal Antibodies, Antirheumatics, Biotechnology, Drugs, Therapy, Rituximab, New York City, United States, North and Central America, CD20 Monoclonal Antibodies, Tyrosine Kinase Inhibitors.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Biotech Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters